This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oka, H. Articles by Lloyd, R. V. Search for Related Content PubMed PubMed Citation Articles by Oka, H. Articles by Lloyd, R. V.

(American Journal of Pathology. 1998;153:1787-1796.)
© 1998 American Society for Investigative Pathology

Regular Articles

Pituitary Adenylate-Cyclase-Activating Polypeptide (PACAP) Binding Sites and PACAP/Vasoactive Intestinal Polypeptide Receptor Expression in Human Pituitary Adenomas

Hidehiro Oka* , Long Jin* , Jean Claude Reubi§ , Xiang Qian* , Bernd W. Scheithauer* , Kiyotaka Fujii , Toru Kameya and Ricardo V. Lloyd*

From the Department of Laboratory Medicine and Pathology,* Mayo Clinic and Mayo Foundation, Rochester, Minnesota; the Departments of Neurosurgery and Pathology, Kitasato University School of Medicine, Kanagawa, Japan; and the Division of Cell Biology and Experimental Cancer Research,§ Institute of Pathology, University of Berne, Berne, Switzerland

Pituitary adenylate-cyclase-activating polypeptide (PACAP) stimulates release of several anterior pituitary hormones by interacting with PACAP receptors on pituitary cells. To learn more about the distribution and possible regulatory roles of PACAP and its receptors in human pituitary adenomas, we investigated the expression of vasoactive intestinal polypeptide (VIP) and PACAP binding sites using receptor autoradiography, PACAP and PACAP/VIP receptor (PVR) mRNAs by reverse transcription polymerase chain reaction (RT-PCR), conventional in situ hybridization, and catalyzed reporter deposition in situ hybridization (CARD-ISH) analyses. PACAP mRNA was expressed in normal human hypothalamus, which was used as a positive control, but not in pituitary adenomas. Receptor autoradiography showed PACAP types I and II binding sites in all groups of pituitary adenomas, except prolactinomas. The highest levels were present in gonadotroph and null cell adenomas. PVR-2 mRNA was expressed in normal pituitaries and in all groups of pituitary adenomas by RT-PCR, whereas PVR-1 and -3 mRNAs were expressed in all groups of pituitary adenomas, except for most prolactinomas. Conventional in situ hybridization studies with digoxigenin-labeled probes demonstrated weak staining for PVR-1, -2, and -3 mRNAs in most tissues. The CARD-ISH technique, which increased the sensitivity of the in situ hybridization method, also revealed PVR-2 mRNA expression in all adenomas, whereas PVR-1 and -3 mRNAs were detected in nearly all adenomas except for prolactinomas. The presence of PACAP mRNA in the hypothalamus, but not in normal anterior pituitary or in pituitary adenomas, and the differential expression of PVRs in adenomas indicate a selective regulatory endocrine and paracrine role of PACAP in normal and neoplastic anterior pituitary cells.

This article has been cited by other articles:

				A. O. L. Wong, W. Li, C. Y. Leung, L. Huo, and H. Zhou Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) as a Growth Hormone (GH)-Releasing Factor in Grass Carp. I. Functional Coupling of Cyclic Adenosine 3',5'-Monophosphate and Ca2+/Calmodulin-Dependent Signaling Pathways in PACAP-Induced GH Secretion and GH Gene Expression in Grass Carp Pituitary Cells Endocrinology, December 1, 2005; 146(12): 5407 - 5424. [Abstract] [Full Text] [PDF]

				S. Schulz, C. Rocken, C. Mawrin, W. Weise, V. Hollt, and S. Schulz Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies Clin. Cancer Res., December 15, 2004; 10(24): 8235 - 8242. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]

				G. Mazzocchi, L. K. Malendowicz, P. Rebuffat, L. Gottardo, and G. G. Nussdorfer Expression and Function of Vasoactive Intestinal Peptide, Pituitary Adenylate Cyclase-Activating Polypeptide, and Their Receptors in the Human Adrenal Gland J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2575 - 2580. [Abstract] [Full Text] [PDF]

				J. C. REUBI In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications Ann. N.Y. Acad. Sci., December 1, 2000; 921(1): 1 - 25. [Abstract] [Full Text] [PDF]

				J. C. Reubi, U. Laderach, B. Waser, J.-O. Gebbers, P. Robberecht, and J. A. Laissue Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin1 Cancer Res., June 1, 2000; 60(11): 3105 - 3112. [Abstract] [Full Text] [PDF]

				D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]

				H. Oka, L. Jin, E. Kulig, B. W. Scheithauer, and R. V. Lloyd Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-{beta}1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line Am. J. Pathol., December 1, 1999; 155(6): 1893 - 1900. [Abstract] [Full Text] [PDF]